-
Media Release
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer
-
Media Release
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
-
Media Release
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
-
Media Release
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
-
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
-
Media Release
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media Release
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
-
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media Release
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color